Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.

被引：10
|
作者：
Bando, Hideaki
Kinoshita, Ichiro
Modi, Shanu
Tsurutani, Junji
Bang, Yung-Jue
Iwata, Hiroji
Sato, Yuta
Nakatani, Shunsuke
Lee, Caleb C.
Sugihara, Masahiro
Okuda, Yasuyuki
Takahashi, Shunji
机构：
[1] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[2] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Showa Univ, Tokyo, Japan
[5] Seoul Natl Univ, Coll Med, Seoul, South Korea
[6] Daiichi Sankyo Co Ltd, Tokyo, Japan
[7] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[8] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.6079
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6079
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2-expressing salivary gland carcinoma: a pooled analysis of two phase I studies
    Takahashi, Shunji
    Bando, Hideaki
    Kinoshita, Ichiro
    Modi, Shanu
    Tsurutani, Junji
    Bang, Yung-Jue
    Sato, Yuta
    Nakatani, Shunsuke
    Lee, Caleb
    Sugihara, Masahiro
    Okuda, Yasuyuki
    Iwata, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (04) : 434 - 443
  • [2] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, Funda
    Anoka, Chiedozie
    Dobrowolska, Anna
    Chaudhry, Anubhavini
    Rowbottom, Jacqui
    Gustavson, Mark
    Puvvada, Soham
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S156 - S156
  • [3] A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of select human epidermal growth factor receptor 2 (HER2)-expressing solid tumors (DESTINY-PanTumor02)
    Meric-Bernstam, Funda
    Anoka, Chiedozie
    Dobrowolska, Anna
    Chaudhry, Anubhavini
    Rowbottom, Jacqui
    Gustavson, Mark
    Puvvada, Soham D.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [4] Trastuzumab deruxtecan (T-DXd) sensitivity in various levels of HER2 expressing gastric cancer cells.
    Yu, Seo Young
    Park, Juin
    Kwon, Woo Sun
    Jeong, Inhye
    Kang, Sun Kyoung
    Bae, Hyun Joo
    Kim, Tae Soo
    Chung, Hyun Cheol
    Rha, Sun Young
    CANCER RESEARCH, 2021, 81 (13)
  • [5] Valemetostat and trastuzumab deruxtecan (T-DXd) in previously treated advanced or metastatic human epidermal growth factor receptor 2 (HER2)-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Shitara, K.
    Enzinger, P. C.
    Mohapatra, A. S.
    Janjigian, Y. Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S200 - S200
  • [6] Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non-small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd)
    Smit, E. F.
    Felip, E.
    Uprety, D.
    Nagasaka, M.
    Nakagawa, K.
    Paz-Ares, L.
    Pacheco, J.
    Li, B. T.
    Planchard, D.
    Baik, C. S.
    Goto, Y.
    Murakami, H.
    Pereira, K. M. C.
    Taguchi, A.
    Kogo, M.
    Kuwahara, Y.
    Zou, M.
    Feng, W.
    Tsuchihashi, Z.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S241 - S242
  • [7] Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINYeLung02 (DL-02)
    Goto, Y.
    Goto, K.
    Kubo, T.
    Ninomiya, K.
    Kim, S-W.
    Ahn, M-J.
    Nakagawa, K.
    Hayashi, H.
    Shimizu, J.
    Kim, D-W.
    Yang, J. C-H.
    Kuo, C-H. S.
    Lee, K. H.
    Yang, T-Y.
    Pereira, K. M. C.
    Taguchi, A.
    Ali, A.
    Cheng, F-C.
    Yonemochi, R.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1666 - S1667
  • [8] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd)
    Nozawa, Kazuki
    Kusudo, Maho
    Kureyama, Nari
    Nakakami, Akira
    Komaki, Rie
    Endo, Yuka
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    CANCER RESEARCH, 2024, 84 (09)
  • [9] A PHASE 1/2 STUDY OF SBT6050 COMBINED WITH TRASTUZUMAB DERUXTECAN (T-DXD) OR TRASTUZUMAB AND TUCATINIB WITH OR WITHOUT CAPECITABINE IN PATIENTS WITH HER2-EXPRESSING OR HER2-AMPLIFIED CANCERS
    Klempner, Samuel
    Strickler, John
    Gourley, Lindsey
    Jacquemont, Celine
    Bhatia, Vinona
    Hunder, Naomi
    Odegard, Valerie
    Piha-Paul, Sarina
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A426 - A426
  • [10] Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
    Dieras, Veronique
    Deluche, Elise
    Lusque, Amelie
    Pistilli, Barbara
    Bachelot, Thomas
    Pierga, Jean-Yves
    Viret, Frederic
    Levy, Christelle
    Salabert, Laura
    Le Du, Fanny
    Dalenc, Florence
    Jouannaud, Christelle
    Venat-Bouvet, Laurence
    Jacquin, Jean-Philippe
    Durando, Xavier
    Petit, Thierry
    Oukhatar, Celine Mahier -Ait
    Filleron, Thomas
    Mosele, Maria Fernanda
    Lacroix-Triki, Magali
    Ducoulombier, Agnes
    Andre, Fabrice
    CANCER RESEARCH, 2022, 82 (04)
12345